Minireviews
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Cardiol. Feb 26, 2014; 6(2): 67-76
Published online Feb 26, 2014. doi: 10.4330/wjc.v6.i2.67
Therapeutic interventions for heart failure with preserved ejection fraction: A summary of current evidence
Muhammad Asrar ul Haq, Chiew Wong, Vivek Mutha, Nagesh Anavekar, Kwang Lim, Peter Barlis, David L Hare
Muhammad Asrar ul Haq, Chiew Wong, Vivek Mutha, Nagesh Anavekar, Peter Barlis, Department of Cardiology, The Northern Hospital, Epping, VIC 3076, Australia
Muhammad Asrar ul Haq, Chiew Wong, Vivek Mutha, Nagesh Anavekar, Kwang Lim, Peter Barlis, David L Hare, Department of Medicine, University of Melbourne, Melbourne 3010, Australia
Author contributions: All authors contributed to this paper equally.
Correspondence to: Dr. Muhammad Asrar ul Haq, MBBS, Department of Cardiology, The Northern Hospital, 185 Cooper Street, Epping, VIC 3076, Australia. asrar.ulhaq@me.com
Telephone: +61-3-80458000 Fax: +61-3-80458045
Received: November 9, 2013
Revised: December 13, 2013
Accepted: January 13, 2014
Published online: February 26, 2014
Abstract

Heart failure with preserved ejection fraction (HFPEF) is common and represents a major challenge in cardiovascular medicine. Most of the current treatment of HFPEF is based on morbidity benefits and symptom reduction. Various pharmacological interventions available for heart failure with reduced ejection fraction have not been supported by clinical studies for HFPEF. Addressing the specific aetiology and aggressive risk factor modification remain the mainstay in the treatment of HFPEF. We present a brief overview of the currently recommended therapeutic options with available evidence.

Keywords: Heart failure, Diastolic dysfunction, Heart failure with preserved ejection fraction, Heart failure with normal ejection fraction

Core tip: Heart failure with preserved ejection fraction (HFPEF) is common and represents a major challenge in cardiovascular medicine. Various pharmacological interventions available for heart failure with reduced ejection fraction have not been supported by clinical studies for HFPEF. This article presents a brief overview of the currently recommended therapeutic strategies for HFPEF.